Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jan;114(1):203–209. doi: 10.1111/j.1476-5381.1995.tb14926.x

Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: role of platelets and cyclo-oxygenase metabolites.

L Argiolas 1, F Fabi 1, P del Basso 1
PMCID: PMC1510170  PMID: 7712019

Abstract

1. The mechanisms of action of platelet activating factor (PAF) in the bronchial and cardiovascular systems have not yet been fully elucidated. In order to characterize better and to ascertain whether the effects of PAF in both these systems may be ascribed to the same mechanisms, we examined the actions of PAF in the heart-lung preparation of guinea-pig (HLP). The role of platelets and of cyclo-oxygenase metabolites was investigated. 2. In HLPs perfused with autologous blood, bolus injections of PAF (4-32 ng) produced major effects at the pulmonary vascular and bronchial levels. Both dose-related pulmonary vascular hypertension and bronchoconstriction produced by PAF were diminished to the same extent (46% and, respectively, 47%) when HLPs were perfused with a medium consisting of homologous red blood cells suspended in physiological solution containing 3.5% dextran (RBC). This suggests that the effects of PAF partially depend on the presence of formed elements. 3. When indomethacin (30 microM) was added to the perfusing blood, the dose-response curve for the pulmonary hypertensive responses produced by PAF was strongly reduced (90%) in comparison to control preparations, whereas the bronchoconstrictor effects of PAF were only partially diminished (23%). These data constitute direct evidence that products of the cyclo-oxygenase pathway exert a major role in the vascular, rather than in the bronchial actions of PAF. 4. In HLPs perfused with RBC containing indomethacin (30 microM), the pulmonary vascular hypertensive responses produced by PAF were almost completely abolished, thus indicating that cyclo-oxygenase products from tissues are involved in these effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
203

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham W. M., Stevenson J. S., Garrido R. A possible role for PAF in allergen-induced late responses: modification by a selective antagonist. J Appl Physiol (1985) 1989 May;66(5):2351–2357. doi: 10.1152/jappl.1989.66.5.2351. [DOI] [PubMed] [Google Scholar]
  2. Bedetti C., Argiolas L., del Basso P. Thromboxane generation and pulmonary reactivity to arachidonic acid in heart-lung preparation of guinea-pig: modulation by PCO2. Prostaglandins Leukot Essent Fatty Acids. 1990 Aug;40(4):243–248. doi: 10.1016/0952-3278(90)90044-l. [DOI] [PubMed] [Google Scholar]
  3. Bedetti C., Del Basso P., Argiolas L., Carpi A. Arachidonic acid and pulmonary function in heart-lung-preparation of guinea-pig: modulation by PCO2. Arch Int Pharmacodyn Ther. 1987 Jan;285(1):98–116. [PubMed] [Google Scholar]
  4. Bellan J. A., Minkes R. K., Hood J. S., McMahon T. J., Higuera T. R., Nossaman B. D., McNamara D. B., Kadowitz P. J. Analysis of pulmonary and systemic vascular responses to platelet-activating factor in the cat. Am J Physiol. 1992 Jul;263(1 Pt 2):H234–H243. doi: 10.1152/ajpheart.1992.263.1.H234. [DOI] [PubMed] [Google Scholar]
  5. Benveniste J., Boullet C., Brink C., Labat C. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br J Pharmacol. 1983 Sep;80(1):81–83. doi: 10.1111/j.1476-5381.1983.tb11052.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bessin P., Bonnet J., Apffel D., Soulard C., Desgroux L., Pelas I., Benveniste J. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol. 1983 Jan 21;86(3-4):403–413. doi: 10.1016/0014-2999(83)90190-5. [DOI] [PubMed] [Google Scholar]
  7. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  8. Chignard M., Le Couedic J. P., Tence M., Vargaftig B. B., Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature. 1979 Jun 28;279(5716):799–800. doi: 10.1038/279799a0. [DOI] [PubMed] [Google Scholar]
  9. Chung K. F., Aizawa H., Leikauf G. D., Ueki I. F., Evans T. W., Nadel J. A. Airway hyperresponsiveness induced by platelet-activating factor: role of thromboxane generation. J Pharmacol Exp Ther. 1986 Mar;236(3):580–584. [PubMed] [Google Scholar]
  10. Dyson M. C., Bellan J. A., Minkes R. K., Beckerman R. C., Wegmann M. J., Braquet P., McNamara D. B., Kadowitz P. J. Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat. J Pharmacol Exp Ther. 1990 Dec;255(3):1320–1327. [PubMed] [Google Scholar]
  11. Goldstein R. E., Feuerstein G. Z., Bradley L. M., Stambouly J. J., Laurindo F. R., Davenport N. J. Cardiovascular effects of platelet-activating factor. Lipids. 1991 Dec;26(12):1250–1256. doi: 10.1007/BF02536542. [DOI] [PubMed] [Google Scholar]
  12. Hamasaki Y., Mojarad M., Saga T., Tai H. H., Said S. I. Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. Am Rev Respir Dis. 1984 May;129(5):742–746. doi: 10.1164/arrd.1984.129.5.742. [DOI] [PubMed] [Google Scholar]
  13. Hu W., Kinnaird A. A., Man R. Y. Mechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused heart. Br J Pharmacol. 1991 May;103(1):1097–1102. doi: 10.1111/j.1476-5381.1991.tb12306.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jancar S., Thériault P., Lauzière M., Braquet P., Sirois P. Paf-induced release of spasmogens from guinea-pig lungs. Br J Pharmacol. 1989 Jan;96(1):153–162. doi: 10.1111/j.1476-5381.1989.tb11795.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Laurindo F. R., Goldstein R. E., Davenport N. J., Ezra D., Feuerstein G. Z. Mechanisms of hypotension produced by platelet-activating factor. J Appl Physiol (1985) 1989 Jun;66(6):2681–2690. doi: 10.1152/jappl.1989.66.6.2681. [DOI] [PubMed] [Google Scholar]
  16. Lefer A. M., Müller H. F., Smith J. B. Pathophysiological mechanisms of sudden death induced by platelet activating factor. Br J Pharmacol. 1984 Sep;83(1):125–130. doi: 10.1111/j.1476-5381.1984.tb10126.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lefort J., Rotilio D., Vargaftig B. B. The platelet-independent release of thromboxane A2 by Paf-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene. Br J Pharmacol. 1984 Jul;82(3):565–575. doi: 10.1111/j.1476-5381.1984.tb10795.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Munoz N. M., Kirchhoff C. F., Strek M. E., Blumenthal R. N., Leff A. R. Effects of PAF on isolated rat airways perfused with blood-free solution. Am J Physiol. 1991 Apr;260(4 Pt 1):L260–L267. doi: 10.1152/ajplung.1991.260.4.L260. [DOI] [PubMed] [Google Scholar]
  19. Popovich K. J., Sheldon G., Mack M., Munoz N. M., Denberg P., Blake J., White S. R., Leff A. R. Role of platelets in contraction of canine tracheal muscle elicited by PAF in vitro. J Appl Physiol (1985) 1988 Aug;65(2):914–920. doi: 10.1152/jappl.1988.65.2.914. [DOI] [PubMed] [Google Scholar]
  20. Saito M., Fujimura M., Ogawa H., Matsuda T. Role of leukotrienes and platelet activating factor in allergic bronchoconstriction and their interactions in guinea pig airway in vivo. Prostaglandins Leukot Essent Fatty Acids. 1993 Aug;49(2):579–585. doi: 10.1016/0952-3278(93)90164-r. [DOI] [PubMed] [Google Scholar]
  21. Sirén A. L., Feuerstein G. Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats. Am J Physiol. 1989 Jul;257(1 Pt 2):H25–H32. doi: 10.1152/ajpheart.1989.257.1.H25. [DOI] [PubMed] [Google Scholar]
  22. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol. 1990 Nov;259(5 Pt 1):C697–C708. doi: 10.1152/ajpcell.1990.259.5.C697. [DOI] [PubMed] [Google Scholar]
  23. Underwood D. C., Kadowitz P. J. Analysis of bronchoconstrictor responses to platelet-activating factor in the cat. J Appl Physiol (1985) 1989 Jul;67(1):377–382. doi: 10.1152/jappl.1989.67.1.377. [DOI] [PubMed] [Google Scholar]
  24. Vargaftig B. B., Lefort J., Chignard M., Benveniste J. Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol. 1980 Jul 25;65(2-3):185–192. doi: 10.1016/0014-2999(80)90391-x. [DOI] [PubMed] [Google Scholar]
  25. Yamanaka S., Miura K., Yukimura T., Okumura M., Yamamoto K. Putative mechanism of hypotensive action of platelet-activating factor in dogs. Circ Res. 1992 May;70(5):893–901. doi: 10.1161/01.res.70.5.893. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES